Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
MONDAY, Feb. 12, 2024 -- For patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who experienced disease progression on first-line chemotherapy, fruquintinib (F) plus paclitaxel (PTX) improves progression free survival...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | HIV AIDS | Pharmaceuticals